Drug Administration Schedule
"Drug Administration Schedule" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
| Descriptor ID |
D004334
|
| MeSH Number(s) |
E02.319.283
|
| Concept/Terms |
Drug Administration Schedule- Drug Administration Schedule
- Administration Schedule, Drug
- Administration Schedules, Drug
- Drug Administration Schedules
- Schedule, Drug Administration
- Schedules, Drug Administration
|
Below are MeSH descriptors whose meaning is more general than "Drug Administration Schedule".
Below are MeSH descriptors whose meaning is more specific than "Drug Administration Schedule".
This graph shows the total number of publications written about "Drug Administration Schedule" by people in this website by year, and whether "Drug Administration Schedule" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1994 | 0 | 7 | 7 |
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 5 | 5 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 8 | 8 |
| 2004 | 0 | 12 | 12 |
| 2005 | 0 | 6 | 6 |
| 2006 | 1 | 6 | 7 |
| 2007 | 0 | 9 | 9 |
| 2008 | 0 | 8 | 8 |
| 2009 | 0 | 8 | 8 |
| 2010 | 0 | 6 | 6 |
| 2011 | 0 | 11 | 11 |
| 2012 | 0 | 14 | 14 |
| 2013 | 0 | 12 | 12 |
| 2014 | 0 | 6 | 6 |
| 2015 | 0 | 12 | 12 |
| 2016 | 0 | 8 | 8 |
| 2017 | 0 | 7 | 7 |
| 2018 | 0 | 9 | 9 |
| 2019 | 0 | 8 | 8 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Administration Schedule" by people in Profiles.
-
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491.
-
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
-
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.
-
Considerations for treatment duration in responders to immune checkpoint inhibitors. J Immunother Cancer. 2021 03; 9(3).
-
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021 02 11; 137(6):751-762.
-
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2020 09; 158(3):631-639.
-
Impact of Daily Preventive Zinc or Therapeutic Zinc Supplementation for Diarrhea on Plasma Biomarkers of Environmental Enteric Dysfunction among Rural Laotian Children: A Randomized Controlled Trial. Am J Trop Med Hyg. 2020 02; 102(2):415-426.
-
Vancomycin dosing in critically ill trauma patients: The VANCTIC Study. J Trauma Acute Care Surg. 2019 11; 87(5):1164-1171.
-
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2.
-
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost. 2019 11; 17(11):1866-1874.